{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:57:28Z","timestamp":1792173448317,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013403","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000}}],"reference-count":207,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013403.pub2","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T09:25:24Z","timestamp":1667467524000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Interventions for the long-term prevention of hereditary angioedema attacks"],"prefix":"10.1002","volume":"2022","author":[{"given":"Nicole","family":"Beard","sequence":"additional","affiliation":[{"name":"Faculty of Science and Technology; University of Canberra; Bruce Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Frese","sequence":"additional","affiliation":[{"name":"Faculty of Science and Technology; University of Canberra; Bruce Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Smertina","sequence":"additional","affiliation":[{"name":"Faculty of Science and Technology; University of Canberra; Bruce Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mere","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics; Macquarie University; Macquarie Park Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Katelaris","sequence":"additional","affiliation":[{"name":"Department of Medicine; Campbelltown Hospital and Western Sydney University; Campbelltown Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Mills","sequence":"additional","affiliation":[{"name":"Faculty of Science and Technology; University of Canberra; Bruce Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1716995","article-title":"Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema","volume":"379","author":"Ayg\u00f6ren\u2011Pu\u0308rsu\u0308n","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0002|cit2","first-page":"723","article-title":"Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study","volume":"73","author":"Bygum","year":"2018","journal-title":"Allergy"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.anai.2018.09.105","article-title":"Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353","volume":"121","author":"Farkas","year":"2018","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0004|cit4","first-page":"724","article-title":"BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study","volume":"73","author":"Magerl","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0005|cit5","first-page":"724","article-title":"Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study","volume":"73","author":"Steiner","year":"2018","journal-title":"Allergy"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"AB23","DOI":"10.1016\/j.jaci.2020.12.122","article-title":"Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial","volume":"147","author":"Anderson","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 109","key":"10.1002\/14651858.CD013403.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/all.14508","article-title":"Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study","volume":"75","author":"Ayg\u00f6ren\u2011Pu\u0308rsu\u0308n","year":"2020","journal-title":"European Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"AB146","DOI":"10.1016\/j.jaci.2020.12.527","article-title":"Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies","volume":"147","author":"Gower","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.anai.2020.08.091","article-title":"Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial","volume":"125","author":"Jacobs","year":"2020","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.anai.2020.08.087","article-title":"Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial","volume":"125","author":"Johnston","year":"2020","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"AB22","DOI":"10.1016\/j.jaci.2020.12.118","article-title":"Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial","volume":"147","author":"Li","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.anai.2020.08.063","article-title":"Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results","volume":"125","author":"Wedner","year":"2020","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013403.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"P2305","DOI":"10.1016\/j.jaip.2021.03.057","article-title":"Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2)","volume":"9","author":"Wedner","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology. In Practice"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jaci.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013403.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1111\/all.14670","article-title":"Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial","volume":"76","author":"Ohsawa","year":"2021","journal-title":"Allergy"},{"issue":"8","key":"10.1002\/14651858.CD013403.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1605767","article-title":"Inhibiting plasma kallikrein for hereditary angioedema prophylaxis","volume":"376","author":"Banerji","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"S101","key":"10.1002\/14651858.CD013403.pub2-BIB0017|cit17","first-page":"107","article-title":"Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema","volume":"70","author":"Banerji","year":"2015","journal-title":"Allergy"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0018|cit18","first-page":"A31","article-title":"Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study","volume":"115","author":"Busse","year":"2015","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"AB251","DOI":"10.1016\/j.jaci.2015.12.906","article-title":"Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema","volume":"137","author":"Jacobs","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0020|cit20","first-page":"A31","article-title":"Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema","volume":"115","author":"Lumry","year":"2015","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013403.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.anai.2017.08.143","article-title":"Use of rescue medication in hereditary angioedema attacks and its relation to attack severity","volume":"119","author":"Anderson","year":"2017","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0022|cit22","first-page":"613","article-title":"C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients","volume":"73","author":"Christiansen","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0023|cit23","first-page":"615","article-title":"Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study","volume":"73","author":"Cicardi","year":"2018","journal-title":"Allergy"},{"issue":"6","key":"10.1002\/14651858.CD013403.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.jaip.2019.01.007","article-title":"Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings","volume":"7","author":"Craig","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology. In Practice"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0025|cit25","first-page":"615","article-title":"Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study","volume":"73","author":"Craig","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013403.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.anai.2017.08.037","article-title":"Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema","volume":"119","author":"Craig","year":"2017","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jadohealth.2017.11.013","article-title":"Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial","volume":"62","author":"Gower","year":"2018","journal-title":"Journal of Adolescent Health"},{"issue":"3","key":"10.1002\/14651858.CD013403.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1089\/ped.2020.1143","article-title":"Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema","volume":"33","author":"Levy","year":"2020","journal-title":"Pediatric Allergy, Immunology, and Pulmonology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"AB45","DOI":"10.1016\/j.jaci.2017.12.148","article-title":"Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456)","volume":"141","author":"Levy","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0030|cit30","first-page":"611","article-title":"Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study","volume":"73","author":"Levy","year":"2018","journal-title":"Allergy"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2500\/aap.2018.39.4164","article-title":"Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial","volume":"39","author":"Li","year":"2018","journal-title":"Allergy and Asthma Proceedings"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"AB45","DOI":"10.1016\/j.jaci.2017.12.147","article-title":"Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study","volume":"141","author":"Li","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13223-019-0362-1","article-title":"Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo\u2011controlled randomized study","volume":"15","author":"Li","year":"2019","journal-title":"Allergy, Asthma and Clinical Immunology"},{"issue":"12","key":"10.1002\/14651858.CD013403.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1613627","article-title":"Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor","volume":"376","author":"Longhurst","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"AB234","DOI":"10.1016\/j.jaci.2016.12.753","article-title":"Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial","volume":"139","author":"Longhurst","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.anai.2017.08.140","article-title":"Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study","volume":"119","author":"Lumry","year":"2017","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"AB233","DOI":"10.1016\/j.jaci.2016.12.751","article-title":"Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study","volume":"139","author":"Lumry","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013403.pub2-BIB0038|cit38","first-page":"29","article-title":"Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456)","volume":"13","author":"Lumry","year":"2017","journal-title":"Allergy, Asthma and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jaip.2017.12.039","article-title":"Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema","volume":"6","author":"Lumry","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology. In Practice"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"AB38","DOI":"10.1016\/j.jaci.2018.12.115","article-title":"Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks","volume":"143","author":"Lumry","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"S101","key":"10.1002\/14651858.CD013403.pub2-BIB0041|cit41","first-page":"60","article-title":"Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use","volume":"70","author":"Magerl","year":"2015","journal-title":"Allergy"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.anai.2018.09.099","article-title":"Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema","volume":"121","author":"Manning","year":"2018","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0043|cit43","first-page":"614","article-title":"On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data","volume":"73","author":"Patel","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0044|cit44","first-page":"614","article-title":"Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study","volume":"73","author":"Riedl","year":"2018","journal-title":"Allergy"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"AB278","DOI":"10.1016\/j.jaci.2014.12.1849","article-title":"Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study","volume":"135","author":"Riedl","year":"2015","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 103","key":"10.1002\/14651858.CD013403.pub2-BIB0046|cit46","first-page":"597","article-title":"Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location","volume":"72","author":"Tarzi","year":"2017","journal-title":"Allergy"},{"issue":"S101","key":"10.1002\/14651858.CD013403.pub2-BIB0047|cit47","first-page":"253","article-title":"Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study","volume":"70","author":"Weller","year":"2015","journal-title":"Allergy"},{"issue":"3","key":"10.1002\/14651858.CD013403.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.anai.2020.05.015","article-title":"Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema","volume":"125","author":"Bernstein","year":"2020","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0049|cit49","first-page":"397","article-title":"Comparison of 40 IU\/kg and 60 IU\/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial","volume":"38","author":"Christiansen","year":"2017","journal-title":"Allergy and Asthma Proceedings"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013403.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.anai.2018.09.107","article-title":"Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks","volume":"121","author":"Craig","year":"2018","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013403.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaip.2019.01.054","article-title":"Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks","volume":"7","author":"Craig","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology. In Practice"},{"issue":"Suppl S4","key":"10.1002\/14651858.CD013403.pub2-BIB0052|cit52","first-page":"27","article-title":"Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema","volume":"49","author":"Katelaris","year":"2019","journal-title":"Internal Medicine Journal"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0053|cit53","first-page":"397","article-title":"Comparison of the safety profiles of 40 IU\/kg and 60 IU\/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial","volume":"38","author":"Li","year":"2017","journal-title":"Allergy and Asthma Proceedings"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013403.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"AB39","DOI":"10.1016\/j.jaci.2018.12.119","article-title":"Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema","volume":"143","author":"Li","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0055|cit55","first-page":"401","article-title":"Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study","volume":"39","author":"Li","year":"2018","journal-title":"Allergy and Asthma Proceedings"},{"issue":"Suppl 103","key":"10.1002\/14651858.CD013403.pub2-BIB0056|cit56","first-page":"100","article-title":"Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study","volume":"72","author":"Longhurst","year":"2017","journal-title":"Allergy"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13023-020-01658-4","article-title":"Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study","volume":"16","author":"Lumry","year":"2021","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"Suppl S4","key":"10.1002\/14651858.CD013403.pub2-BIB0058|cit58","first-page":"27","article-title":"Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden","volume":"49","author":"Zuraw","year":"2019","journal-title":"Internal Medicine Journal"},{"issue":"26","key":"10.1002\/14651858.CD013403.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJM197612232952602","article-title":"Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities","volume":"295","author":"Gelfand","year":"1976","journal-title":"New England Journal of Medicine"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.anai.2017.08.040","article-title":"Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study","volume":"119","author":"Banerji","year":"2017","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.anai.2018.09.014","article-title":"Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study","volume":"121","author":"Banerji","year":"2018","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"20","key":"10.1002\/14651858.CD013403.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"issue":"Suppl 231","key":"10.1002\/14651858.CD013403.pub2-BIB0063|cit63","first-page":"28S","article-title":"Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study","volume":"148","author":"Banerji","year":"2018","journal-title":"Swiss Medical Weekly"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0064|cit64","first-page":"288","article-title":"Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study","volume":"73","author":"Bernstein","year":"2018","journal-title":"Allergy"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"AB43","DOI":"10.1016\/j.jaci.2018.12.131","article-title":"Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE)","volume":"143","author":"Busse","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0066|cit66","first-page":"722","article-title":"Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study","volume":"73","author":"Cicardi","year":"2018","journal-title":"Allergy"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"AB21","DOI":"10.1016\/j.jaci.2020.12.116","article-title":"Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies","volume":"147","author":"Craig","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013403.pub2-BIB0068|cit68","first-page":"A63","article-title":"Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis","volume":"15","author":"Gagnon","year":"2019","journal-title":"Allergy, Asthma, and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013403.pub2-BIB0069|cit69","first-page":"A66","article-title":"Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study","volume":"15","author":"Hebert","year":"2019","journal-title":"Allergy, Asthma and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"AB38","DOI":"10.1016\/j.jaci.2018.12.116","article-title":"Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies","volume":"143","author":"Jacobs","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013403.pub2-BIB0071|cit71","first-page":"10","article-title":"Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study","volume":"15","author":"Jain","year":"2019","journal-title":"Allergy, Asthma and Clinical Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.anai.2018.09.114","article-title":"Lanadelumab safety and immunogenicity: results from the phase 3 HELP study","volume":"121","author":"Johnston","year":"2018","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"AB47","DOI":"10.1016\/j.jaci.2017.12.152","article-title":"Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study","volume":"141","author":"Johnston","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"11","key":"10.1002\/14651858.CD013403.pub2-BIB0074|cit74","first-page":"1524","article-title":"Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study","volume":"48","author":"Longhurst","year":"2018","journal-title":"Clinical and Experimental Allergy"},{"issue":"11","key":"10.1002\/14651858.CD013403.pub2-BIB0075|cit75","first-page":"OP.019","article-title":"Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study","volume":"48","author":"Longhurst","year":"2018","journal-title":"Clinical and Experimental Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14680","article-title":"Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study","volume":"76","author":"Lumry","year":"2021","journal-title":"Allergy"},{"issue":"Suppl 231","key":"10.1002\/14651858.CD013403.pub2-BIB0077|cit77","first-page":"28S","article-title":"Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study","volume":"148","author":"Lumry","year":"2018","journal-title":"Swiss Medical Weekly"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"AB47","DOI":"10.1016\/j.jaci.2017.12.154","article-title":"Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study","volume":"141","author":"Lumry","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0079|cit79","first-page":"289","article-title":"High responder rates in lanadelumab-treated patients in the phase 3 HELP study","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0080|cit80","first-page":"289","article-title":"Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study","volume":"73","author":"Maurer","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 231","key":"10.1002\/14651858.CD013403.pub2-BIB0081|cit81","first-page":"36S","article-title":"Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study","volume":"148","author":"Maurer","year":"2018","journal-title":"Swiss Medical Weekly"},{"issue":"11","key":"10.1002\/14651858.CD013403.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1111\/all.14416","article-title":"Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks","volume":"75","author":"Riedl","year":"2020","journal-title":"Allergy"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"AB47","DOI":"10.1016\/j.jaci.2017.12.153","article-title":"Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study","volume":"141","author":"Riedl","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"AB41","DOI":"10.1016\/j.jaci.2018.12.123","article-title":"Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study","volume":"143","author":"Schmaier","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"AB45","DOI":"10.1016\/j.jaci.2018.12.138","article-title":"Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study","volume":"143","author":"Sexton","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"AB40","DOI":"10.1016\/j.jaci.2018.12.122","article-title":"Exposure-response analyses of lanadelumab in patients with hereditary angioedema","volume":"143","author":"Wang","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013403.pub2-BIB0087|cit87","first-page":"A64","article-title":"Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy","volume":"15","author":"Yang","year":"2019","journal-title":"Allergy, Asthma and Clinical Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0088|cit88","first-page":"722","article-title":"Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study","volume":"73","author":"Zanichelli","year":"2018","journal-title":"Allergy"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0089|cit89","first-page":"A29","article-title":"Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE)","volume":"109","author":"Bernstein","year":"2012","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"AB234","DOI":"10.1016\/j.jaci.2016.12.752","article-title":"Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE)","volume":"139","author":"Bernstein","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"AB33","DOI":"10.1016\/j.jaci.2013.12.146","article-title":"Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE)","volume":"133","author":"Dayno","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jpeds.2012.11.030","article-title":"Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children","volume":"162","author":"Lumry","year":"2013","journal-title":"Journal of Paediatrics"},{"issue":"S99","key":"10.1002\/14651858.CD013403.pub2-BIB0093|cit93","first-page":"491","article-title":"Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study","volume":"69","author":"Lumry","year":"2014","journal-title":"Allergy"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013403.pub2-BIB0094|cit94","first-page":"A105","article-title":"Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study","volume":"111","author":"Lumry","year":"2013","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2500\/aap.2014.35.3783","article-title":"Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks","volume":"35","author":"Lumry","year":"2014","journal-title":"Allergy and Asthma Proceedings"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0096|cit96","first-page":"420","article-title":"Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks","volume":"94","author":"Riedl","year":"2011","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0097|cit97","first-page":"A100","article-title":"Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks","volume":"105","author":"Zuraw","year":"2010","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013403.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013403.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"938.e1","DOI":"10.1016\/j.amjmed.2012.02.020","article-title":"Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema","volume":"125","author":"Zuraw","year":"2012","journal-title":"American Journal of Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"AB192","DOI":"10.1016\/j.jaci.2014.12.1563","article-title":"Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema","volume":"135","author":"Lumry","year":"2015","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013403.pub2-BIB0101|cit101","first-page":"A106","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks","volume":"10","author":"Reshef","year":"2017","journal-title":"World Allergy Organization Journal"},{"issue":"3","key":"10.1002\/14651858.CD013403.pub2-BIB0102|cit102","first-page":"237","article-title":"Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks","volume":"38","author":"Riedl","year":"2017","journal-title":"Allergy and Asthma Proceedings"},{"issue":"6","key":"10.1002\/14651858.CD013403.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2500\/aap.2016.37.4006","article-title":"Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema","volume":"37","author":"Riedl","year":"2016","journal-title":"Allergy and Asthma Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2500\/aap.2017.38.4025","article-title":"Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase","volume":"38","author":"Weller","year":"2017","journal-title":"Allergy and Asthma Proceedings"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013403.pub2-BIB0105|cit105","first-page":"O","article-title":"Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study","volume":"13","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2017","journal-title":"Allergy, Asthma and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/pai.13060","article-title":"A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema","volume":"30","author":"Ayg\u00f6ren-Pu\u0308rsu\u0308n","year":"2019","journal-title":"Pediatric Allergy and Immunology"},{"issue":"Suppl 103","key":"10.1002\/14651858.CD013403.pub2-BIB0107|cit107","first-page":"101","article-title":"The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children","volume":"72","author":"Farkas","year":"2017","journal-title":"Allergy"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.anai.2018.09.112","article-title":"C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy","volume":"121","author":"Jacobson","year":"2018","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0109|cit109","first-page":"718","article-title":"Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention","volume":"73","author":"Martinez-Saguer","year":"2018","journal-title":"Allergy"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"AB41","DOI":"10.1016\/j.jaci.2018.12.125","article-title":"Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE)","volume":"143","author":"Soteres","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"10102","key":"10.1002\/14651858.CD013403.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(17)31963-3","article-title":"Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial","volume":"390","author":"Riedl","year":"2017","journal-title":"Lancet"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"AB231","DOI":"10.1016\/j.jaci.2016.12.744","article-title":"Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial","volume":"139","author":"Yang","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013403.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"AB192","DOI":"10.1016\/j.jaci.2014.12.1562","article-title":"Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE)","volume":"135","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2015","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013403.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaci.2016.03.043","article-title":"Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat","volume":"138","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"AB278","DOI":"10.1016\/j.jaci.2014.12.1848","article-title":"BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study","volume":"135","author":"Magerl","year":"2015","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0116|cit116","first-page":"414","article-title":"Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients","volume":"73","author":"Magerl","year":"2018","journal-title":"Allergy"},{"issue":"9","key":"10.1002\/14651858.CD013403.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/all.13466","article-title":"Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study","volume":"73","author":"Riedl","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0118|cit118","first-page":"720","article-title":"Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study","volume":"73","author":"Farkas","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 105","key":"10.1002\/14651858.CD013403.pub2-BIB0119|cit119","first-page":"287","article-title":"Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study","volume":"73","author":"Lumry","year":"2018","journal-title":"Allergy"},{"issue":"Suppl 231","key":"10.1002\/14651858.CD013403.pub2-BIB0120|cit120","first-page":"26S","article-title":"Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study","volume":"148","author":"Lumry","year":"2018","journal-title":"Swiss Medical Weekly"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaip.2019.01.021","article-title":"Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study","volume":"7","author":"Lumry","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology. In Practice"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2340\/00015555-1835","article-title":"Health-related quality of life in Danish patients with hereditary angioedema","volume":"95","author":"Aabom","year":"2015","journal-title":"Acta Dermato-venereologica"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13223-017-0203-z","article-title":"Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey","volume":"13","author":"Aberer","year":"2017","journal-title":"Allergy, Asthma, and Clinical Immunology"},{"issue":"8061","key":"10.1002\/14651858.CD013403.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(78)91254-0","article-title":"Intermittent therapy with danazol in hereditary angioedema","volume":"1","author":"Agostoni","year":"1978","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1398-9995.1978.tb01537.x","article-title":"Hepatic function and fibrinolysis in patients with hereditary angioedema undergoing long-term treatment with tranexamic acid","volume":"33","author":"Agostoni","year":"1978","journal-title":"Allergy"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0091-6749(80)90181-5","article-title":"Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema","volume":"65","author":"Agostoni","year":"1980","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02904745","article-title":"The management of hereditary angioedema","volume":"13","author":"Agostoni","year":"1983","journal-title":"Ricerca in Clinica e in Laboratorio"},{"issue":"8","key":"10.1002\/14651858.CD013403.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/all.12186","article-title":"Risk of angioedema following invasive or surgical procedures in HAE Type I and II \u2013 the natural history","volume":"68","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2013","journal-title":"Allergy"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2500\/aap.2013.34.3645","article-title":"Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women","volume":"34","author":"Baker","year":"2013","journal-title":"Allergy and Asthma Proceedings"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13223-019-0328-3","article-title":"Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks","volume":"15","author":"Bernstein","year":"2019","journal-title":"Allergy, Asthma, and Clinical Immunology"},{"issue":"12","key":"10.1002\/14651858.CD013403.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.clinthera.2008.12.021","article-title":"Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema","volume":"30","author":"Birjmohun","year":"2008","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.0954-6820.1972.tb04818.x","article-title":"Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study","volume":"192","author":"Blohm\u00e9","year":"1972","journal-title":"Acta Medica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1081-1206(10)60424-3","article-title":"Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients","volume":"100","author":"Bork","year":"2008","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000319213","article-title":"Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week","volume":"154","author":"Bork","year":"2011","journal-title":"International Archives of Allergy and Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/all.13076","article-title":"Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII)","volume":"72","author":"Bork","year":"2017","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jaip.2016.12.033","article-title":"Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients","volume":"5","author":"Busse","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology. In Practice"},{"issue":"S99","key":"10.1002\/14651858.CD013403.pub2-BIB0137|cit137","first-page":"581","article-title":"Results of a phase 1a, single ascending dose study of DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein under investigation for long term prophylaxis of hereditary angioedema","volume":"69","author":"Chyung","year":"2014","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0091-6749(97)70095-2","article-title":"Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients","volume":"2","author":"Cicardi","year":"1997","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"AB252","DOI":"10.1016\/j.jaci.2015.12.908","article-title":"Pharmacodynamic effect of DX-2930 on plasma kallikrein in hereditary angioedema patients","volume":"137","author":"Davis-Lorton","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2007.10.048","article-title":"Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P","volume":"121","author":"Drouet","year":"2008","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0141|cit141","unstructured":"An open-label exploratory phase II study of the safety and prophylactic effect of a weekly 50 U\/kg rC1INH treatment in asymptomatic patients with hereditary C1INH deficiency (HAE) \u2013 OPERA clinicaltrialsregister.eu\/ctr-search\/trial\/2009-010736-18\/HU"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0142|cit142","unstructured":"Pharmacokinetics and safety of human pasteurised C1-inhibitor concentrate (Berinert\/CE1145) in subjects with congenital C1-INH deficiency clinicaltrialsregister.eu\/ctr-search\/trial\/2010-019670-32\/IT"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00228-009-0771-z","article-title":"The effect of long-term danazol prophylaxis on liver function in hereditary angioedema \u2013 a longitudinal study","volume":"66","author":"Farkas","year":"2010","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jaci.2012.08.001","article-title":"Prophylactic therapy in children with hereditary angioedema","volume":"131","author":"Farkas","year":"2013","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013403.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2362.2010.02402.x","article-title":"Long-term efficacy of danazol treatment in hereditary angioedema","volume":"41","author":"F\u00fcst","year":"2011","journal-title":"European Journal of Clinical Investigation"},{"issue":"3","key":"10.1002\/14651858.CD013403.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2011.11.005","article-title":"Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor\u00ae): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety","volume":"142","author":"Hofstra","year":"2012","journal-title":"Clinical Immunology (Orlando, Fla.)"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0147|cit147","unstructured":"Patient registry study of Berinert\u00ae in normal clinical practice clinicaltrials.gov\/show\/NCT01108848"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0148|cit148","unstructured":"Postmarketing immunogenicity study in HAE subjects treated with Berinert clinicaltrials.gov\/show\/NCT01467947"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0149|cit149","unstructured":"A study to evaluate the clinical pharmacology and safety of C1-esterase inhibitor administered by the subcutaneous route clinicaltrials.gov\/show\/NCT01576523"},{"issue":"10","key":"10.1002\/14651858.CD013403.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/all.12658","article-title":"Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate","volume":"70","author":"Zuraw","year":"2015","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0151|cit151","unstructured":"A study to evaluate the safety and pharmacokinetics of two formulations of C1-esterase inhibitor clinicaltrials.gov\/show\/NCT01760343"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jaci.2008.12.361","article-title":"Evaluation of prodromal symptoms concurrent with hereditary angioedema therapy","volume":"123","author":"Sharma","year":"2009","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0153|cit153","first-page":"31","article-title":"Danazol therapy in hereditary angioedema","volume":"28","author":"Sweet","year":"1980","journal-title":"Henry Ford Hospital Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.atherosclerosis.2007.09.025","article-title":"Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients","volume":"198","author":"Szegedi","year":"2008","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaci.2004.12.1130","article-title":"Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema","volume":"115","author":"Sz\u00e9plaki","year":"2005","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 103","key":"10.1002\/14651858.CD013403.pub2-BIB0156|cit156","first-page":"148","article-title":"Pharmacokinetics (PK) and pharmacodynamics (PD) of c1 esterase inhibitor (c1-IHN) for prophylaxis of angioedema attacks in patients (PTS) with hereditary angioedema (HAE)","volume":"72","author":"Wang","year":"2017","journal-title":"Allergy"},{"issue":"25","key":"10.1002\/14651858.CD013403.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1056\/NEJM199606203342503","article-title":"Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate","volume":"334","author":"Waytes","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0158|cit158","first-page":"430","article-title":"Adverse effects of danazol prophylaxis in female patients with hereditary angioedema due to C1-INH deficiency (HAE-C1-INH)","volume":"97","author":"Zotter","year":"2013","journal-title":"Allergy: European Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0159|cit159","first-page":"211","article-title":"Long-term therapy of hereditary angioedema","volume":"70","author":"Zhang","year":"1990","journal-title":"Chung-Hua i Hsueh Tsa Chih"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0160|cit160","unstructured":"A study to investigate CSL312 in subjects with hereditary angioedema (HAE) clinicaltrials.gov\/ct2\/show\/NCT03712228"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0161|cit161","unstructured":"CSL312 (Garadacimab) in the prevention of hereditary angioedema attacks clinicaltrials.gov\/ct2\/show\/NCT04656418"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0162-3109(99)00107-1","article-title":"Angioedema due to angiotensin-converting enzyme inhibitors","volume":"44","author":"Agostoni","year":"1999","journal-title":"Immunopharmacology"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0163|cit163","unstructured":"Australasian Society of Clinical Immunology and Allergy Hereditary angioedema (HAE) position paper allergy.org.au\/images\/docs\/ASCIA_HP_Position_Paper_HAE_2020_Aug_Update.pdf"},{"issue":"3","key":"10.1002\/14651858.CD013403.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaci.2017.05.020","article-title":"Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema","volume":"141","author":"Bafunno","year":"2018","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"20","key":"10.1002\/14651858.CD013403.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/all.13270","article-title":"Hereditary angioedema with a mutation in the plasminogen gene","volume":"73","author":"Bork","year":"2018","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12955-018-1028-2","article-title":"Defining the minimally clinically important difference of the SF-36 physical function subscale for paediatric CFS\/ME: triangulation using three different methods","volume":"16","author":"Brigden","year":"2018","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"AB194","DOI":"10.1016\/j.jaci.2014.12.1570","article-title":"Development and characterization of an anti-FXIIa monoclonal antibody for the treatment of hereditary angioedema","volume":"135","author":"Cao","year":"2015","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013403.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"AB230","DOI":"10.1016\/j.jaci.2016.12.741","article-title":"Preclinical characterization of BCX7353, an oral plasma kallikrein inhibitor, for the treatment of hereditary angioedema (HAE)","volume":"139","author":"Chen","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0091-6749(97)70095-2","article-title":"Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients","volume":"99","author":"Cicardi","year":"1997","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0171|cit171","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587","volume-title":"Statistical power analysis for the behavioral sciences","author":"Cohen","year":"1988"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0172|cit172","first-page":"388","article-title":"Hereditary angioedema: therapeutic effect of danazol on C4 and C1 esterase inhibitors","volume":"64","author":"Fabiani","year":"1990","journal-title":"Annals of Allergy"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0173|cit173","unstructured":"Danocrine label ID: 3061327 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/017557s033s039s040s041s042lbl.pdf 1 9"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7326\/0003-4819-84-5-580","article-title":"Hereditary angioedema: the clinical syndrome and its management","volume":"84","author":"Frank","year":"1976","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/art.1780221118","article-title":"Effect of sex hormones on the complement-related clinical disorder of hereditary angioedema","volume":"22","author":"Frank","year":"1979","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"e20160575","DOI":"10.1542\/peds.2016-0575","article-title":"Management of children with hereditary angioedema due to C1 inhibitor deficiency","volume":"138","author":"Frank","year":"2016","journal-title":"Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD013403.pub2-BIB0177|cit177","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013402","article-title":"Interventions for the treatment of acute hereditary angioedema attacks","author":"Frese","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12016-016-8543-x","article-title":"Genetics of hereditary angioedema revisited","volume":"51","author":"Germenis","year":"2016","journal-title":"Clinical Reviews in Allergy and Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/jcp.55.2.145","article-title":"A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency","volume":"55","author":"Gompels","year":"2002","journal-title":"Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"GRADE Working Group","year":"2004","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0181|cit181","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2147\/TCRM.S86293","article-title":"Diagnosis and screening of patients with hereditary angioedema in primary care","volume":"12","author":"Henao","year":"2016","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0183|cit183","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0184|cit184","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0185|cit185","first-page":"6","article-title":"New treatments for hereditary angioedema","volume":"23","author":"Johnson","year":"2018","journal-title":"Skin Therapy Letters"},{"issue":"34","key":"10.1002\/14651858.CD013403.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","article-title":"Inhibition of plasma kallikrein by a highly specific active site blocking antibody","volume":"289","author":"Kenniston","year":"2014","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"10.1002\/14651858.CD013403.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1537-2995.1998.38698326333.x","article-title":"A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema","volume":"38","author":"Kunschak","year":"1998","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0188|cit188","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s12016-016-8575-2","article-title":"The humanistic, societal and pharmaco-economic burden of angioedema","volume":"51","author":"Longhurst","year":"2016","journal-title":"Clinical Reviews in Allergy and Immunology"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fmed.2017.00245","article-title":"Optimum use of acute treatments for hereditary angioedema: evidence-based expert consensus","volume":"4","author":"Longhurst","year":"2018","journal-title":"Frontiers in Medicine"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0192|cit192","doi-asserted-by":"crossref","unstructured":"Lopes Veronez C Csuka D Sheikh FR Zuraw BL Farkas H Bork K The expanding spectrum of mutations in hereditary angioedema Journal of Allergy and Clinical Immunology. In Practice 2021 9 6 2229 34 10.1016\/j.jaip.2021.03.008","DOI":"10.1016\/j.jaip.2021.03.008"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fmed.2018.00022","article-title":"Hereditary angioedema: the economics of treatment of an orphan disease","volume":"5","author":"Lumry","year":"2018","journal-title":"Frontiers in Medicine"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40413-017-0180-1","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema \u2013 the 2017 revision and update","volume":"11","author":"Maurer","year":"2018","journal-title":"World Allergy Organization Journal"},{"issue":"5","key":"10.1002\/14651858.CD013403.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Medical Care"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0196|cit196","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1081-1206(10)61121-0","article-title":"Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain","volume":"94","author":"Roche","year":"2005","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"3","key":"10.1002\/14651858.CD013403.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2249.2007.03438.x","article-title":"An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema","volume":"149","author":"Tarzi","year":"2007","journal-title":"Clinical and Experimental Immunology"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0199|cit199","unstructured":"US HAE Association Diagnosing HAE www.haea.org\/diagnosis.php"},{"issue":"8","key":"10.1002\/14651858.CD013403.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The Angioedema Quality of Life Questionnaire (AE-QoL) \u2013 assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.anai.2010.01.024","article-title":"Economic costs associated with acute attacks and long-term management of hereditary angioedema","volume":"104","author":"Wilson","year":"2010","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD013403.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/cei.12379","article-title":"Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients","volume":"178","author":"Wintenberger","year":"2014","journal-title":"Clinical and Experimental Immunology"},{"issue":"2","key":"10.1002\/14651858.CD013403.pub2-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1475-6773.2005.0l374.x","article-title":"A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease","volume":"40","author":"Wyrwich","year":"2005","journal-title":"Health Services Research"},{"issue":"4","key":"10.1002\/14651858.CD013403.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/07853890.2016.1162909","article-title":"Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment","volume":"48","author":"Zeerleder","year":"2016","journal-title":"Annals of Medicine"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1750-1172-9-44","article-title":"The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency","volume":"9","author":"Zotter","year":"2014","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1002\/14651858.CD013403.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMcp0803977","article-title":"Hereditary angioedema","volume":"359","author":"Zuraw","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013403.pub2-BIB0207|cit207","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013403","article-title":"Interventions for the long-term prevention of hereditary angioedema attacks","author":"Beard","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:34:55Z","timestamp":1759793695000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013403.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":207,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013403.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}